| Literature DB >> 36267286 |
Li Lu1,2, Yuan Xiong1,2, Ze Lin1,2, Xiangyu Chu1,2, Adriana C Panayi3,4, Yiqiang Hu1,2, Juan Zhou5, Bobin Mi1,2, Guohui Liu1,2.
Abstract
Extensive research has implicated inflammation and oxidative stress in the development of multiple diseases, such as diabetes, hepatitis, and arthritis. Kinsenoside (KD), a bioactive glycoside component extracted from the medicinal plant Anoectochilus roxburghii, has been shown to exhibit potent anti-inflammatory and anti-oxidative abilities. In this review, we summarize multiple effects of KD, including hepatoprotection, pro-osteogenesis, anti-hyperglycemia, vascular protection, immune regulation, vision protection, and infection inhibition, which are partly responsible for suppressing inflammation signaling and oxidative stress. The protective action of KD against dysfunctional lipid metabolism is also associated with limiting inflammatory signals, due to the crosstalk between inflammation and lipid metabolism. Ferroptosis, a process involved in both inflammation and oxidative damage, is potentially regulated by KD. In addition, we discuss the physicochemical properties and pharmacokinetic profiles of KD. Advances in cultivation and artificial synthesis techniques are promising evidence that the shortage in raw materials required for KD production can be overcome. In addition, novel drug delivery systems can improve the in vivo rapid clearance and poor bioavailability of KD. In this integrated review, we aim to offer novel insights into the molecular mechanisms underlying the therapeutic role of KD and lay solid foundations for the utilization of KD in clinical practice.Entities:
Keywords: ROS; cytokine; herbal medicine; inflammation; kinsenoside; oxidative stress; signal pathway
Year: 2022 PMID: 36267286 PMCID: PMC9576948 DOI: 10.3389/fphar.2022.1009550
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1The whole plant of Anoectochilus roxburghii and the chemical structural formula of KD.
Basic information on KD-related treatment objects and modalities.
| Object | Stimulation | Animal model | Route of KD | Dosage of KD | Intervention time | References |
|---|---|---|---|---|---|---|
| ICR mice | CCl4 | Chronic hepatitis | Oral gavage | 17.5–270 mg/kg | 3–8 w |
|
| ICR mice | CCl4 | Hepatic fibrosis | Oral gavage | 50–150 mg/kg | 3 w |
|
| BALB/c mice | TAA | Hepatic fibrosis | Oral gavage | 36–180 mg/kg | 12 w |
|
| C57BL/6 mice | DEN | Hepatic damage | Intraperitoneal injection | 5 mg/kg | 4 w |
|
| C57BL/6J mice | Ethanol | Acute alcoholic liver injury | Oral gavage | 10–40 mg/kg | 31 days |
|
| C57BL/6J mice | Ethanol, CCl4 | Alcoholic liver injury | Oral gavage | 20–40 mg/kg | 9 w |
|
| SD rats | EE | Cholestatic liver injury | Oral gavage | 50–200 mg/kg | 10 days |
|
| C57BL/6 mice | ConA | Autoimmune hepatitis | Oral gavage | 10–30 mg/kg | 3–5 days |
|
| C57BL/6J mice | CCl4 | Hepatic fibrosis | Oral gavage | 10–30 mg/kg | 8 w |
|
| Wistar rats | STZ | Diabetes | Oral gavage | 5–15 mg/kg | 21 days |
|
| ICR mice | STZ | Diabetes | Oral gavage | 50–100 mg/kg | 21 days |
|
| C57BL/6J mice | ACLT | Osteoarthritis | Intraperitoneal injection | 2.5–10 mg/kg | 4 w |
|
| SD rats | MSU crystals | Gouty arthritis | Intra-articular injection | 2.5–10 mg/kg | 3 days |
|
| DBA/1 J mice | Type II collagen | Rheumatoid arthritis | Oral gavage | 100–300 mg/kg | 21 days |
|
| ICR mice | OVX | Osteoporosis | Oral gavage | 100–300 mg/kg | 4 w |
|
| SD rats | Puncture | IDD | Intraperitoneal injection | 10 mg/kg | 4 w |
|
| ICR mice | LPS | Endotoxic shock | Intraperitoneal injection | 100–300 mg/kg | 3 days |
|
| C57BL/6 mice | LPS | Acute lung injury | Oral gavage | 100 mg/kg | 7 days |
|
| C57BL/6 mice | HFD | Hyperlipemia | Oral gavage | 50–100 mg/kg | 2 w |
|
CCl4, carbon tetrachloride; TAA, thioacetamide; DEN, diethylnitrosamine; EE, 17α-ethinylestradiol; ConA, concanavalin A; STZ, streptozotocin; ACLT, anterior cruciate ligament transection; MSU, monosodium urate; OVX, ovariectomized; LPS, lipopolysaccharide; HFD, high fat diet; IDD, intervertebral disc degeneration.
FIGURE 2Various stimuli provoked inflammation response and oxidative stress in multiple cell types of liver tissues, attributed to activating MAPKs, STATs, NF-κB, and AP-1 and increasing the generation of ROS. KD was capable of impeding pro-inflammatory signaling pathways and suppressing the activities of ROS-producing enzymes, thereby improving subsequent structural disarrangement and functional dysregulation.
FIGURE 3KD administration alleviated endothelial dysfunction triggered by hyperglycemia. AGEs displayed an increased level under the environment of high glucose, which then induced intracellular NOX activation and ROS overload, accompanied by NF-κB activation and expression of inflammatory factors. KD elevated the contents of antioxidants and NO to disrupt the interaction of ROS with NF-κB, thereby weakening endothelial injury.
FIGURE 4The mechanism of the actions underlying protective effects of KD on the skeletal and articular system. Macrophages phenotype reprogramming, proportion change of T cell subtypes, amelioration of chondrocytes and ECs apoptosis and inhibition of pro-inflammatory cytokines generation were involved in KD-related beneficial roles in arthritis management. Promotion of ROS scavenging and abolishment of osteoclast transdifferentiation were associated with the therapeutic action of KD on intervertebral disc degeneration and osteoporosis.
FIGURE 5KD exhibits effective roles in prohibiting the development of several diseases including hepatitis, diabetes, arthritis, osteoporosis, and lung damage via versatile molecular mechanisms. Other illnesses, such as atherosclerosis, fracture disunion, and refractory ulcer were had potentials to be treated by KD, which were worthy to be further elucidated. The improvements in the cultivation, extraction and synthesis techniques were likely to overcome the deficiency of KD-producing raw materials and met the demands of medical care. Multiple drug delivery systems had been developed to enhance the stability, bioavailability, and safety of phytochemicals in vivo.